Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

264
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
264
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.1K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

393
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
393
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

227
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
227
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

619
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
619
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

511
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tilmanocept Labels Granulomas in Cardiac Sarcoidosis.

Journal of cardiac failure·2026
Same author

CCR6 is essential for effective immunity against <i>Mycobacterium tuberculosis</i> infection in mice.

Infection and immunity·2026
Same author

pH-responsive substrate switching in mycobacterial type VII ESX secretion.

mSphere·2026
Same author

pH-responsive substrate switching in mycobacterial Type VII ESX secretion.

bioRxiv : the preprint server for biology·2026
Same author

Granuloma dual RNA-seq reveals composite transcriptional programs driven by neutrophils and necrosis within tuberculous granulomas.

Science advances·2026
Same author

Mapping unsolved lipidomes accelerates lipid discovery in major bacterial pathogens.

bioRxiv : the preprint server for biology·2025

Related Experiment Videos

Consequential drug combinations for tuberculosis treatments.

Charlie J Pyle1, David M Tobin2

  • 1Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.

Cell Systems
|November 18, 2021
PubMed
Summary
This summary is machine-generated.

Researchers developed a new computational framework to predict the best tuberculosis drug combinations. This approach uses dose-response data and animal studies to prioritize effective antitubercular drug regimens for improved therapies.

Related Experiment Videos

Area of Science:

  • * Pharmacology
  • * Computational Biology
  • * Infectious Disease

Background:

  • * Tuberculosis (TB) treatment necessitates complex, multi-drug regimens.
  • * Optimizing these regimens is crucial for developing improved TB therapies.
  • * Current methods for selecting drug combinations can be inefficient.

Purpose of the Study:

  • * To develop a predictive framework for prioritizing antitubercular drug regimens.
  • * To integrate diverse data types for a comprehensive approach to drug combination selection.
  • * To facilitate the discovery of more effective tuberculosis treatments.

Main Methods:

  • * Integration of extensive dose-response measurements for drug combinations.
  • * Utilization of in vivo animal data to assess efficacy and toxicity.
  • * Application of computational analysis to build a predictive model.

Main Results:

  • * A novel predictive framework was established for antitubercular drug regimen prioritization.
  • * The framework successfully integrates in vitro and in vivo data.
  • * Demonstrated potential for optimizing multi-drug therapy selection.

Conclusions:

  • * The developed framework offers a systematic approach to identifying optimal drug combinations for TB.
  • * This predictive model can accelerate the development of improved tuberculosis therapies.
  • * Computational integration of experimental data is key to advancing anti-TB drug discovery.